| Name | Springs Valley Meadows |
|---|---|
| Location | 457 S Sr 145, French Lick, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 74 |
| Occupancy Rate | 71.22% |
| Medicare ID (CCN) | 155126 |
| Legal Business Name | The Health And Hospital Corporation Of Marion County |
| Ownership Type | Government - City/county |
| NPI Number | 1124190087 |
| Organization Name | INDIANA HEALTH & REHABILITATION CENTERS |
| Doing Business As | MEDCO HEALTH & REHABILITATION CENTER |
| Address | 457 S State Road 145, French Lick, IN 47432 |
| Phone Number | 812-936-9991 |
News Archive
Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.
Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.
Various chemical modifications in the genome determine whether genes are read or deactivated. Methyl labels in the DNA play a key role in this "epigenetic" regulation of gene activity.
In a bold move meant to advance the care and services provided to the disability community, Courage Center and Allina Health announced today that their boards of directors have approved a proposed merger between the Sister Kenny Rehabilitation Institute and Courage Center.
› Verified 4 days ago
| NPI Number | 1265133482 |
| Address | 457 S State Road 145, French Lick, IN 47432 |
| Phone Number | 812-936-9991 |
News Archive
Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.
Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.
Various chemical modifications in the genome determine whether genes are read or deactivated. Methyl labels in the DNA play a key role in this "epigenetic" regulation of gene activity.
In a bold move meant to advance the care and services provided to the disability community, Courage Center and Allina Health announced today that their boards of directors have approved a proposed merger between the Sister Kenny Rehabilitation Institute and Courage Center.
› Verified 4 days ago
| NPI Number | 1457697377 |
| Organization Name | THE HEALTH AND HOSPITAL CORPORATION OF MARION COUNTY |
| Doing Business As | SPRINGS VALLEY MEADOWS |
| Address | 457 S State Road 145, French Lick, IN 47432 |
| Phone Number | 812-936-9991 |
News Archive
Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.
Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.
Various chemical modifications in the genome determine whether genes are read or deactivated. Methyl labels in the DNA play a key role in this "epigenetic" regulation of gene activity.
In a bold move meant to advance the care and services provided to the disability community, Courage Center and Allina Health announced today that their boards of directors have approved a proposed merger between the Sister Kenny Rehabilitation Institute and Courage Center.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.
Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.
Various chemical modifications in the genome determine whether genes are read or deactivated. Methyl labels in the DNA play a key role in this "epigenetic" regulation of gene activity.
In a bold move meant to advance the care and services provided to the disability community, Courage Center and Allina Health announced today that their boards of directors have approved a proposed merger between the Sister Kenny Rehabilitation Institute and Courage Center.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $3250 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.94 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.45 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.89 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 4.04 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 10.4 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.58 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.05 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.37 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.18 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 9.34 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14.59 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.65 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 77.54 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 97.3 | 82.93 |
News Archive
Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.
Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.
Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.
Various chemical modifications in the genome determine whether genes are read or deactivated. Methyl labels in the DNA play a key role in this "epigenetic" regulation of gene activity.
In a bold move meant to advance the care and services provided to the disability community, Courage Center and Allina Health announced today that their boards of directors have approved a proposed merger between the Sister Kenny Rehabilitation Institute and Courage Center.
› Verified 4 days ago